Press releases
ENYO Pharma receives a €2.5 million grant from EU under the Horizon2020/SME Instrument Phase 2 programme for its project MIMESIS
Lyon, December 5, 2016 – ENYO Pharma, a biopharmaceutical company currently focused on developing treatments for viral infections, today announced that it has received a grant of €2.5 million in response to its application to the highly competitive SME Instrument Phase 2 funding programme (6% success rate).
ENYO Pharma strengthens its management team to support its strategy of international growth
Lyon, November 7, 2016 – ENYO Pharma strengthens its management team to support its strategy of international growth.
ENYO Pharma announces closing of a €22 million funding round
Lyon, February 3, 2016 – ENYO Pharma announces closing of a €22 million funding round.
ENYO Pharma strengthens its arsenal of hepatitis B potential therapies
Lyon, November 25, 2015 – ENYO Pharma, a biopharmaceutical company focused on developing treatments for acute and chronic viral infections, is announcing that it has obtained a license to a key patent enabling it to use agonists of the farnesoid X receptor (FXR) as hepatitis B treatments.
POXEL and ENYO Pharma Sign License Agreement on POXEL’s FXR Agonists Program
Lyon, France, May 6, 2015 – POXEL SA (Euronext: POXEL), a biopharmaceutical company developing innovative drugs to treat type 2 diabetes, and ENYO Pharma SAS, a newly-formed company focused on the treatment of acute and chronic viral infections, today announced the signing of a license agreement under which ENYO will gain access to Poxel’s FXR (farnesoid X receptor) agonist compounds for infection-related indications with Poxel retaining rights regarding therapeutic indications centered on its core expertise.
